Skvarka Jan
SEC insider (Form 3/4/5 filer). CIK 0001838042. Director at Zentalis Pharmaceuticals, Inc. (ZNTL) and 1 other issuer. 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 16, 2026. Located in BOSTON, MA.
Companies Skvarka Jan has filed insider reports for
- Zentalis Pharmaceuticals, Inc. (ZNTL): Director
- Monte Rosa Therapeutics, Inc. (GLUE): Director
Skvarka Jan
CIK: 0001838042
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 16, 2026ZNTL
Zentalis Pharmaceuticals, Inc.
AwardDirect57.1K shares- - Jun 11, 2026GLUE
Monte Rosa Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
25.8K shares- - Jun 17, 2025ZNTL
Zentalis Pharmaceuticals, Inc.
AwardDirect57.6K shares- - Jun 13, 2025GLUE
Monte Rosa Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
30.7K shares- - Jan 31, 2025ZNTL
Zentalis Pharmaceuticals, Inc.
PurchaseDirect60K shares at avg. $1.72$103K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 16, 2026 |  ZNTL Zentalis Pharmaceuticals, Inc. | Award | 57,100 | - | $0 | Direct |
| Jun 11, 2026 |  GLUE Monte Rosa Therapeutics, Inc. | Award Stock Option (Right to Buy) | 25,800 | - | - | Direct |
| Jun 17, 2025 | ZNTL Zentalis Pharmaceuticals, Inc. | Award | 57,603 | - | - | Direct |
| Jun 13, 2025 | GLUE Monte Rosa Therapeutics, Inc. | Award Stock Option (Right to Buy) | 30,700 | - | - | Direct |
| Jan 31, 2025 | ZNTL Zentalis Pharmaceuticals, Inc. | Purchase | 60,000 | $1.72 | $103,446 | Direct |
1-5 of 5 transactions